Log in to your Inderes Free account to see all free content on this page.

Stenocare

1.60 DKK

-5.33 %

Less than 1K followers

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-5.33 %

+1.59 %

+24.03 %

+264.46 %

+120.35 %

+48.42 %

-70.65 %

-79.74 %

-88.28 %

Stenocare is a Danish supplier of medical cannabis. Stenocare is the first player to have started sale of medical cannabis-based oils in Denmark. The company is now looking towards further European markets for its products. Stenocare is based in Randers, Denmark.

Market cap

69.45M DKK

Turnover

331.78K DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2.

2026

Annual report '25

All

Press releases

3rd party

ShowingAll content types

Press release11/21/2025, 5:41 AM

BioStock: Stenocare acquires Canngros

Press release11/19/2025, 6:56 PM

STENOCARE share analyst's comments on the CannGros acquisition

Regulatory press release11/18/2025, 8:59 AM

STENOCARE: Correction of total shares issued and total nominal share capital:

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/17/2025, 4:56 PM

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Regulatory press release11/17/2025, 4:01 PM

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Regulatory press release10/22/2025, 6:00 AM

STENOCARE: Interim report third quarter 2025

Regulatory press release8/27/2025, 7:30 PM

Trading in STENOCARE shares by closely related party to board member

Regulatory press release8/21/2025, 6:00 AM

STENOCARE: Interim report second quarter 2025

Third party research5/19/2025, 8:05 AM

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Regulatory press release5/15/2025, 9:36 AM

Communiqué from the Annual General Meeting of STENOCARE

Third party research5/9/2025, 5:25 AM

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Regulatory press release5/8/2025, 6:00 AM

STENOCARE: Interim report first quarter 2025

Press release5/2/2025, 12:35 PM

Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

Regulatory press release4/22/2025, 1:01 PM

Notice to Annual General Meeting in STENOCARE A/S

Third party research4/4/2025, 7:20 AM

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible ...

Press release4/3/2025, 6:00 AM

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Press release3/31/2025, 6:00 AM

STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

Press release3/28/2025, 12:25 PM

STENOCARE interview with Proinvestor.com - Annual Report 2024

Regulatory press release3/27/2025, 7:01 AM

STENOCARE A/S publishes Annual Report 2024

Third party research3/6/2025, 1:17 PM

STENOCARE: All Focus on Astrum - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.